Login to Your Account

'Back to the Future' as GSK Hopes to Boost Innovation

By Nuala Moran
Staff Writer

Wednesday, February 8, 2012
LONDON – Splitting its internal research effort into dozens of small teams, with each focusing on a particular disease or pathway, is on track to solve GlaxoSmithKline plc's productivity woes and push its return on investment in R&D to 14 percent.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription